Radiotherapy in Primary Mediastinal Lymphoma (pml)

Instituto Mexicano del Seguro Social

Status: Completed

Conditions: Adjuvant Radiotherapy on Complete Remission Patients

Treatments: Radiation: no drugs

Study type: Observational

Funder types: Other

Identifiers

NCT01230008

katty7

katt7 (Other Identifier)

Details and patient eligibility

About

The use of Rituximab has been proposed to be useful and avoid the use of radiotherapy in diffuse large B-cell lymphoma with bulky disease.We assess efficacy of adjuvant radiotherapy in patients treated with R-CHOP

Enrollment: 198 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Diagnosis of primary mediastinal lymphoma No previous treatment performance status < 2 HIV, Hepatis B and C negative Normal :Renal, hepatic, pulmonary and cardiac function

Exclusion criteria

pregnancy

Trial design

198 participants in 2 patient groups

Radiotherapy in mediastinal lymphoma

Description:

Radiotherapy will no be administered in patients treated with R-CHOP

Radiotherapy in primary mediastinal lymphoma

Description:

Patients with primary mediastinal lymphoma will be treated with R-CHOP as induction therapy, if complete response is achieved, they were allocated to received or no (control group) adjuvatn radiotherapy, 3.5 G to mediastinal site.

Treatment:

Radiation: no drugs